

PTC THERAPEUTICS, INC.  
Form 4  
May 11, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SCHMERTZLER MICHAEL

2. Issuer Name and Ticker or Trading Symbol  
PTC THERAPEUTICS, INC.  
[PTCT]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
1300 VALLEY ROAD  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
05/07/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)

NEW CANAAN, CT 06840

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |                             |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|-----------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |                             |
| Common Stock                    |                                      |  |                                |   | 26,766 <sup>(1)</sup>   | D  |   |                             |
| Common Stock                    | 05/07/2015                           |  | J <sup>(2)</sup>               |   | 1,125,722   | D  | \$ 0 4,569 <sup>(3)</sup>                             | See footnote <sup>(3)</sup> |
| Common Stock                    | 05/11/2015                           |  | J <sup>(4)</sup>               |   | 848   | D  | <sup>(4)</sup> 3,721 <sup>(5)</sup>                   | See footnote <sup>(5)</sup> |
| Common Stock                    |                                      |  |                                |   |   |  | 1,320,369   | See footnote <sup>(6)</sup> |

Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price or Amount of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|------------------------------|
| Stock Option (Right to Buy)                | \$ 51  |                                      |  |                                |   | 01/02/2016 01/01/2025                                    | Common Stock  | 24,000                       |
| Stock Option (Right to Buy)                | \$ 27.05   |                                      |  |                                |   | 01/28/2015 01/27/2024                                    | Common Stock  | 20,000                       |
| Stock Option (Right to Buy)                | \$ 10.85   |                                      |  |                                |   | <u>(7)</u> 05/15/2023                                    | Common Stock  | 60,000                       |
| Stock Option (Right to Buy)                | \$ 218.4   |                                      |  |                                |   | <u>(8)</u> 01/10/2022                                    | Common Stock  | 276                          |
| Stock Option (Right to Buy)                | \$ 490.8   |                                      |  |                                |   | <u>(8)</u> 04/27/2021                                    | Common Stock  | 276                          |
| Stock Option (Right to Buy)                | \$ 1,149.6   |                                      |  |                                |   | <u>(8)</u> 02/02/2020                                    | Common Stock  | 216                          |
|  | \$ 508.8   |                                      |  |                                |   | <u>(8)</u> 10/07/2019                                    |   | 266                          |

|                                      |          |     |            |                 |     |
|--------------------------------------|----------|-----|------------|-----------------|-----|
| Stock<br>Option<br>(Right to<br>Buy) |          |     |            | Common<br>Stock |     |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 735.6 | (8) | 01/25/2018 | Common<br>Stock | 166 |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 735.6 | (8) | 07/14/2018 | Common<br>Stock | 83  |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 626.4 | (8) | 04/18/2017 | Common<br>Stock | 125 |
| Stock<br>Option<br>(Right to<br>Buy) | \$ 392.4 | (8) | 03/01/2016 | Common<br>Stock | 90  |

## Reporting Owners

| Reporting Owner Name / Address                                  | Relationships |           |         |       |
|---|---------------|-----------|---------|-------|
|   | Director      | 10% Owner | Officer | Other |
| SCHMERTZLER MICHAEL<br>1300 VALLEY ROAD<br>NEW CANAAN, CT 06840 | X             |           |         |       |

## Signatures

/s/ Colleen Diver Johnson,  
attorney-in-fact

05/11/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents 26,766 shares of common stock of the Issuer ("common stock") directly held by the reporting person.

Represents final distributions in kind, without consideration to the applicable limited partners, of common stock of the Issuer effected by Credit Suisse First Boston Equity Partners (Bermuda), L.P. (879,798 shares) and Credit Suisse First Boston Equity Partners, L.P. (245,924 shares). The shares of common stock distributed were initially received by these funds upon the automatic conversion of preferred stock at the time of the Issuer's initial public offering in June 2013. The reporting person is a managing director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P. The reporting person disclaims beneficial ownership of the distributed shares of common stock except to the extent of his pecuniary interest therein.

(3) Consists of (i) 3,487 shares of common stock held by EMA Private Equity Fund 1999 LP; (ii) 848 shares of common stock held by Credit Suisse First Boston U S Executive Advisors LP; and (iii) 234 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.

## Edgar Filing: PTC THERAPEUTICS, INC. - Form 4

- Represents dispositions pursuant to Rule 144 of 848 shares of common stock at a weighted average price of \$55.6807 per share by Credit Suisse First Boston U S Executive Advisors LP. Although included in the reporting person's prior ownership reports, the reporting person disclaims beneficial ownership of the disposed securities.
- (4)

- Consists of (i) 3,487 shares of common stock held by EMA Private Equity Fund 1999 LP; and (ii) 234 shares of common stock held by Credit Suisse First Boston Finders and Screeners LP. The reporting person disclaims beneficial ownership of the shares of common stock held by these entities.
- (5)

- Represents shares of common stock held by Section Six Partners, L.P. The reporting person is a general and limited partner of, and trustee of certain family trusts holding interests in, Section Six Partners, L.P. The reporting person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein.
- (6)

- This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vested on August 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
- (7)

- (8) Currently exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.